View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsVeradigm 将来の成長Future 基準チェック /06Veradigmの収益と利益は、それぞれ年間0.5%と30.4%減少すると予測されています。EPS は年間18.4%で 減少すると予想されています。自己資本利益率は 3 年後に-4.3%になると予測されています。主要情報-30.4%収益成長率-18.37%EPS成長率Healthcare Services 収益成長23.8%収益成長率-0.5%将来の株主資本利益率-4.30%アナリストカバレッジLow最終更新日08 Feb 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Feb 13Veradigm Brings Patient Voice to Healthcare Research with New Real-World Data Survey SolutionVeradigm announced a new patient-reported outcomes (PRO) survey capability that brings the patient voice directly into real-world evidence generation. The new solution gives life sciences organizations timely, privacy-preserving insights directly from patients, adding essential context to clinical and observational research. Built on Veradigm's FollowMyHealth patient engagement platform, the capability enables individuals to securely share their experiences through an account they own and manage. Patients receive project-specific requests through trusted channels within FollowMyHealth, ensuring responses are authentic and relevant. Targeting logic helps reach the right patients quickly, and integrated consent and compensation streamline participation. Connecting the Full Patient Journey: Because of its nationally representative, diverse healthcare provider footprint, Veradigm is uniquely positioned to combine first-party clinical data from independent practices with direct patient input and point-of-care reach. This connected view helps innovators understand what truly drives outcomes and act with greater confidence. In 2025, Veradigm successfully completed and published a study demonstrating the feasibility of collecting PROs through FollowMyHealth and linking them with real-world data. The study validated the approach and confirmed the value of capturing patient experience alongside clinical information. By adding patient-reported information to existing real-world data, life sciences organizations gain a fuller picture of symptom burden, treatment experience, adherence, and quality-of-life factors. Benefits include: Patient-centered insights often missing from clinical documentation; Connected clinical and patient input for richer context; Trusted engagement through an established patient platform; Precision outreach to relevant patient groups; Integrated consent and compensation to reduce friction.New Risk • Feb 09New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 30% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Earnings are forecast to decline by an average of 30% per year for the foreseeable future.お知らせ • Jan 29Veradigm Launches New AI Application for Powerful Revenue Cycle Insights for Independent PracticesVeradigm announced the launch of a new AI-enabled application for Veradigm Revenue Cycle Services (RCS) clients, designed to deliver faster, deeper revenue cycle insights and strengthen the value of ongoing performance reviews for independent practices. Independent practices continue to face rising administrative complexity and financial pressure, driven by denials, payment variability, staffing constraints, and limited analytic visibility into what is driving revenue leakage. Veradigm RCS directly addresses these challenges by combining technology, expertise, and operational support to help practices improve cash flow and reduce revenue cycle burden. The new AI-enabled application is a web-based analytics workspace used by Veradigm's Revenue Cycle Services teams as part of their performance review process with clients. Instead of manually preparing and stitching together reports, analysts can now access an AI-generated view of denial trends, payment patterns, and operational bottlenecks in a single interface. The system automatically highlights anomalies, expands audit coverage, and surfaces emerging issues, allowing practices to see what is driving revenue leakage and where intervention is needed. Veradigm's new AI-enabled application is expected to reduce manual performance review preparation time by up to 25%, surface denial and payment trends automatically, and apply machine intelligence to expand audit coverage and reduce avoidable rework. Veradigm RCS is an end-to-end revenue cycle management solution designed to optimize financial performance for medical practices, with teams supporting everything from communicating with health plans to coding and claims, while integrating into existing electronic health record (EHR) and practice management workflows. Veradigm RCS consistently delivers top-tier financial outcomes for independent practices, achieving a 98% first-pass clean claims rate, 99% net collections, and 3-5% average revenue improvement in the first year.お知らせ • Jan 16Veradigm and Meperia Launch Industry-First 8-Way Match EDI Platform to Strengthen Healthcare Supply Chain IntegrityVeradigm and Meperia announced a strategic collaboration to launch a next-generation Electronic Data Interchange (EDI) solution, purpose-built for healthcare. This new EDI platform is designed to eliminate the friction, cost, and complexity of traditional EDI platforms through an industry-first 8-Way Match Framework. Built on a secure, cloud-based infrastructure supporting more than 16 million transactions, $5 billion in purchase volume, and unlimited supplier connections, the platform delivers hospital-first data governance tailored to provider needs and healthcare sustainability goals. The solution automatically validates each transaction against contracts, receipts, invoices, item masters, and rebate terms--minimizing errors, preventing overpayments, ensuring contract compliance, and enhancing rebate capture--all without manual intervention. By combining Veradigm's healthcare ERP platform spanning finance, supply chain, and point-of-use workflows, with Meperia's expertise in data governance, the collaboration delivers true end-to-end supply chain integrity.業績と収益の成長予測BST:AL21 - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2026585N/AN/AN/A112/31/2025585N/AN/AN/A212/31/2024591-46-59-24312/31/20236146475105312/31/2022588-2083116N/A9/30/20221,52911682161N/A6/30/20221,522125107189N/A3/31/20221,512148-91-11N/A12/31/2021577128-118-77N/A9/30/2021806-14-373-319N/A6/30/20211,027-48-388-322N/A3/31/20211,255-96-183-98N/A12/31/2020556-28-149-104N/A9/30/20201,428-143-1584N/A6/30/20201,507-134-4467N/A3/31/20201,582-263-7937N/A12/31/20191,633-238-7446N/A9/30/20191,763-197-11920N/A6/30/20191,751-203-138-1N/A3/31/20191,74834-12915N/A12/31/20181,618-39-6668N/A9/30/20181,5167073188N/A6/30/20181,53354105237N/A3/31/20181,518-187120262N/A12/31/20171,498-183122279N/A9/30/20171,714-21067257N/A6/30/20171,657-19165246N/A3/31/20171,618-48105269N/A12/31/20161,38631145269N/A9/30/20161,470-2N/A268N/A6/30/20161,4323N/A255N/A3/31/20161,39710N/A229N/A12/31/20151,386-2N/A212N/A9/30/20151,382-21N/A180N/A6/30/20151,373-41N/A154N/A3/31/20151,372-56N/A141N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: AL21の収益は今後 3 年間で減少すると予測されています (年間-30.4% )。収益対市場: AL21の収益は今後 3 年間で減少すると予測されています (年間-30.4% )。高成長収益: AL21の収益は今後 3 年間で減少すると予測されています。収益対市場: AL21の収益は今後 3 年間で減少すると予想されています (年間-0.5% )。高い収益成長: AL21の収益は今後 3 年間で減少すると予測されています (年間-0.5% )。一株当たり利益成長率予想将来の株主資本利益率将来のROE: AL21 3 年以内に赤字になると予測されています。成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/02/16 07:27終値2026/02/10 00:00収益2022/12/31年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Veradigm Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。29 アナリスト機関Jasper HellwegArgus Research CompanyMatthew GillmorBairdLawrence MarshBarclays26 その他のアナリストを表示
お知らせ • Feb 13Veradigm Brings Patient Voice to Healthcare Research with New Real-World Data Survey SolutionVeradigm announced a new patient-reported outcomes (PRO) survey capability that brings the patient voice directly into real-world evidence generation. The new solution gives life sciences organizations timely, privacy-preserving insights directly from patients, adding essential context to clinical and observational research. Built on Veradigm's FollowMyHealth patient engagement platform, the capability enables individuals to securely share their experiences through an account they own and manage. Patients receive project-specific requests through trusted channels within FollowMyHealth, ensuring responses are authentic and relevant. Targeting logic helps reach the right patients quickly, and integrated consent and compensation streamline participation. Connecting the Full Patient Journey: Because of its nationally representative, diverse healthcare provider footprint, Veradigm is uniquely positioned to combine first-party clinical data from independent practices with direct patient input and point-of-care reach. This connected view helps innovators understand what truly drives outcomes and act with greater confidence. In 2025, Veradigm successfully completed and published a study demonstrating the feasibility of collecting PROs through FollowMyHealth and linking them with real-world data. The study validated the approach and confirmed the value of capturing patient experience alongside clinical information. By adding patient-reported information to existing real-world data, life sciences organizations gain a fuller picture of symptom burden, treatment experience, adherence, and quality-of-life factors. Benefits include: Patient-centered insights often missing from clinical documentation; Connected clinical and patient input for richer context; Trusted engagement through an established patient platform; Precision outreach to relevant patient groups; Integrated consent and compensation to reduce friction.
New Risk • Feb 09New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 30% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Earnings are forecast to decline by an average of 30% per year for the foreseeable future.
お知らせ • Jan 29Veradigm Launches New AI Application for Powerful Revenue Cycle Insights for Independent PracticesVeradigm announced the launch of a new AI-enabled application for Veradigm Revenue Cycle Services (RCS) clients, designed to deliver faster, deeper revenue cycle insights and strengthen the value of ongoing performance reviews for independent practices. Independent practices continue to face rising administrative complexity and financial pressure, driven by denials, payment variability, staffing constraints, and limited analytic visibility into what is driving revenue leakage. Veradigm RCS directly addresses these challenges by combining technology, expertise, and operational support to help practices improve cash flow and reduce revenue cycle burden. The new AI-enabled application is a web-based analytics workspace used by Veradigm's Revenue Cycle Services teams as part of their performance review process with clients. Instead of manually preparing and stitching together reports, analysts can now access an AI-generated view of denial trends, payment patterns, and operational bottlenecks in a single interface. The system automatically highlights anomalies, expands audit coverage, and surfaces emerging issues, allowing practices to see what is driving revenue leakage and where intervention is needed. Veradigm's new AI-enabled application is expected to reduce manual performance review preparation time by up to 25%, surface denial and payment trends automatically, and apply machine intelligence to expand audit coverage and reduce avoidable rework. Veradigm RCS is an end-to-end revenue cycle management solution designed to optimize financial performance for medical practices, with teams supporting everything from communicating with health plans to coding and claims, while integrating into existing electronic health record (EHR) and practice management workflows. Veradigm RCS consistently delivers top-tier financial outcomes for independent practices, achieving a 98% first-pass clean claims rate, 99% net collections, and 3-5% average revenue improvement in the first year.
お知らせ • Jan 16Veradigm and Meperia Launch Industry-First 8-Way Match EDI Platform to Strengthen Healthcare Supply Chain IntegrityVeradigm and Meperia announced a strategic collaboration to launch a next-generation Electronic Data Interchange (EDI) solution, purpose-built for healthcare. This new EDI platform is designed to eliminate the friction, cost, and complexity of traditional EDI platforms through an industry-first 8-Way Match Framework. Built on a secure, cloud-based infrastructure supporting more than 16 million transactions, $5 billion in purchase volume, and unlimited supplier connections, the platform delivers hospital-first data governance tailored to provider needs and healthcare sustainability goals. The solution automatically validates each transaction against contracts, receipts, invoices, item masters, and rebate terms--minimizing errors, preventing overpayments, ensuring contract compliance, and enhancing rebate capture--all without manual intervention. By combining Veradigm's healthcare ERP platform spanning finance, supply chain, and point-of-use workflows, with Meperia's expertise in data governance, the collaboration delivers true end-to-end supply chain integrity.